F S&P 500
5,244.25 -2.00 (-0.04%) F Dow Jones
39,620.00 -22.00 (-0.06%) F Nasdaq
18,256.00 +1.00 (+0.01%) E-mini Russell 2000 Index Futur
2,068.90 +1.00 (+0.05%) Petróleo
78.07 -0.19 (-0.24%) Oro
2,365.40 -9.60 (-0.40%)
Imunon, Inc. (IMNN)
Fuera de horario:
Imunon, Inc.
997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100
https://imunon.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 33
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael H. Tardugno | Executive Chairman | N/D | N/D | 1951 |
| Mr. Jeffrey W. Church CPA | CFO, Executive VP & Corporate Secretary | 632.02k | N/D | 1957 |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Executive VP & Chief Scientific Officer | 632.26k | N/D | 1960 |
| Mr. Timothy J. Tumminello CPA | Chief Accounting Officer & Controller | 108.31k | N/D | 1958 |
| Dr. Sebastien Hazard M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1972 |
Descripción
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Imunon, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
